Cargando…

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation

IMPORTANCE: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with antiplatelet (AP) drugs in addition to OAC, with or w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fox, Keith A. A., Velentgas, Priscilla, Camm, A. John, Bassand, Jean-Pierre, Fitzmaurice, David A., Gersh, Bernard J., Goldhaber, Samuel Z., Goto, Shinya, Haas, Sylvia, Misselwitz, Frank, Pieper, Karen S., Turpie, Alexander G. G., Verheugt, Freek W. A., Dabrowski, Elizabeth, Luo, Kaiyi, Gibbs, Liza, Kakkar, Ajay K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137686/ https://www.ncbi.nlm.nih.gov/pubmed/32101311 http://dx.doi.org/10.1001/jamanetworkopen.2020.0107

Ejemplares similares

Comparative effectiveness of oral anticoagulants in everyday practice
por: Camm, A John, et al.
Publicado: (2021)

Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry
por: Cools, Frank, et al.
Publicado: (2021)

New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF
por: Goto, Shinichi, et al.
Publicado: (2019)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation
por: Fox, Keith A A, et al.
Publicado: (2017)

GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
por: Fox, Keith A A, et al.
Publicado: (2021)

Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF
por: Camm, Alan John, et al.
Publicado: (2023)

The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events
por: Atar, Dan, et al.
Publicado: (2020)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF
por: Bassand, Jean-Pierre, et al.
Publicado: (2016)

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
por: Camm, A John, et al.
Publicado: (2017)

Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry
por: Mantovani, Lorenzo G., et al.
Publicado: (2023)

Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
por: Kakkar, Ajay K., et al.
Publicado: (2013)

Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF
por: Camm, Christian Fielder, et al.
Publicado: (2022)

Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry
por: Fox, Keith A A, et al.
Publicado: (2022)

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation
por: Bassand, Jean-Pierre, et al.
Publicado: (2018)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry
por: Haas, Sylvia, et al.
Publicado: (2016)

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry
por: Goto, Shinya, et al.
Publicado: (2019)

Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registry
por: Apenteng, Patricia, et al.
Publicado: (2023)

Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents
por: Bassand, Jean-Pierre
Publicado: (2012)

Anticoagulation in patients with mechanical heart valves: follow the guidelines!
por: Verheugt, Freek W.A.
Publicado: (2015)

Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
por: Lim, Toon Wei, et al.
Publicado: (2023)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
por: Haas, Sylvia, et al.
Publicado: (2022)

Antiplatelet therapy with CABG: chaos in the Netherlands
por: Verheugt, F. W. A.
Publicado: (2017)

Antiplatelet Prescription in Atrial Fibrillation: Association with a Low Rate of Anticoagulation
por: Chopard, Romain, et al.
Publicado: (2018)

Erratum to: Antiplatelet therapy with CABG: chaos in the Netherlands
por: Verheugt, F. W. A.
Publicado: (2017)

Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade
por: Atar, Dan, et al.
Publicado: (2014)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Surgeon's guide to anticoagulant and antiplatelet medications part two: antiplatelet agents and perioperative management of long-term anticoagulation
por: Yeung, Louise Y Y, et al.
Publicado: (2016)

Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019
por: Serrano Jr., Carlos V., et al.
Publicado: (2019)

Outpatient cervical brachytherapy in the setting of ongoing antiplatelet therapy or oral anticoagulation
por: Valakh, Vladimir, et al.
Publicado: (2018)

The new oral anticoagulants in atrial fibrillation: an update
por: Verheugt, F. W. A.
Publicado: (2013)

Practical Guide for Anticoagulant and Antiplatelet Reversal in Clinical Practice
por: Aldhaeefi, Mohammed, et al.
Publicado: (2023)

Anticoagulant Activities of Indobufen, an Antiplatelet Drug
por: Liu, Jia, et al.
Publicado: (2018)

Impact of anticoagulation and antiplatelet therapy on dialysis catheter fibrin sheath formation
por: Linch, Forrest B., et al.
Publicado: (2022)

Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism
por: Turpie, Alexander G.G.
Publicado: (2012)

Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs
por: Hofmeier, Kathrin Scherer
Publicado: (2015)

Anticoagulants/antiplatelets: Bleeding: 14 case reports
Publicado: (2020)

Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD‐AF
por: Ambrosio, Giuseppe, et al.
Publicado: (2021)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k769hfp3uikblt51mg4n9mb8eb